GLSI (Greenwich LifeSciences, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by GLSI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-30 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-07-29 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-07-27 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-01-15 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-01-14 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-01-05 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2026-01-02 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-12-19 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-11-28 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-11-17 | Snehal Patel | CEO and CFO | A | — | — |
| 2025-11-12 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-11-04 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-04-29 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-04-22 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-04-08 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-04-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-13 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-08 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-06 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-03 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2025-01-02 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-12-27 | Frank Joseph Daugherty | Chief Medical Officer | A | — | — |
| 2024-12-27 | Eric Rothe | Director | A | — | — |
| 2024-12-27 | Kenneth Hallock | Director | A | — | — |
| 2024-12-27 | Snehal Patel | CEO and CFO | A | — | — |
| 2024-12-27 | Jaye Thompson | VP Clinical Reg Affairs | A | — | — |
| 2024-12-27 | David McWilliams | Director | A | — | — |
| 2024-11-25 | Jaye Thompson | VP Clinical Reg Affairs | Buy | — | — |
| 2024-09-30 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-09-16 | Jaye Thompson | VP Clinical Reg Affairs | Buy | — | — |
| 2024-08-08 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-08-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-08-05 | Jaye Thompson | VP Clinical Reg Affairs | Buy | — | — |
| 2024-07-24 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-07-22 | Jaye Thompson | VP Clinical Reg Affairs | Buy | — | — |
| 2024-06-17 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-04-03 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-03-26 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-03-22 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-03-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-03-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-03-06 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-02-21 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2024-02-20 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2023-11-14 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2023-11-07 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2023-10-31 | Jaye Thompson | VP Clinical Reg Affairs | Buy | — | — |
| 2023-10-30 | Snehal Patel | CEO and CFO | Buy | — | — |
| 2023-10-27 | Snehal Patel | CEO and CFO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and CFO | 8,324,288 | — |
| — | 10%+ Owner | 2,405,670 | — |
| — | Director | 794,308 | — |
| — | Director | 620,301 | — |
| — | Director | 313,226 | — |
| — | VP Clinical Reg Affairs | 264,148 | — |
| — | Chief Medical Officer | 90,121 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GLSI quote page; the site-wide leaderboard is on the insider transactions hub.